



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ed CROZE et al.

BOX SEQUENCE

Serial No.: 09/912,252

Examiner: Unassigned

Filed: July 25, 2001

Group Art Unit: 1645

For: USE OF THE INTEFERON RECEPTOR 2c POLYPEPTIDE CHAIN TO
ENHANCE THE ANTI-GROWTH EFFECTS OF TYPE I INTERFERONS


**RESPONSE TO NOTICE TO COMPLY
WITH SEQUENCE DISCLOSURE REQUIREMENTS**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper is responsive to the Communication from the Examiner dated October 11, 2002. Please insert the attached sequence listing. A copy of the sequence listing in computer readable form, along with a statement, is also being provided.

Respectfully submitted,





Anthony J. Zelano
Registration No. 27,969
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO,
& BRANIGAN, P.C.
Arlington Courthouse Plaza I, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BERLX-79

Filed: December 11, 2002



APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/912,252	07/25/2001	Ed Croze	BERLX-79

23599
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
2200 CLARENDON BLVD.
SUITE 1400
ARLINGTON, VA 22201

CONFIRMATION NO. 4123

FORMALITIES LETTER



OC000000008941023

Date Mailed: 10/11/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Ngain

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY